GlassScriptPhysician profile
Eliyahu Shemesh
NPI 1952472250
$14,020.32
in general payments reported to CMS, 2019-2025
26 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2021: $3,134 · 2022: $2,469 · 2023: $4,140 · 2024: $2,688 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,755 · Food and Beverage: $2,648 · Education: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,755.38 |
| Food and Beverage | $2,647.69 |
| Education | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,124.67 | 2019-2024 | Da Vinci Surgical System, Davinci Xi |
| Medtronic, INC. | $1,639.40 | 2022-2024 | Interstim |
| Abbvie INC. | $493.70 | 2023-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $436.57 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Davol INC. | $297.41 | 2019-2025 | Phasix Mesh |
| Ardelyx, INC. | $181.01 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.85 | 2023-2025 | Xifaxan |
| Genzyme Corporation | $88.46 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $75.54 | 2024-2025 | Vowst |
| Lilly USA, LLC | $70.09 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $60.16 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Merck Sharp & Dohme LLC | $43.50 | 2024 | Dificid, Zinplava |
| Covidien LP | $40.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $39.09 | 2023 | |
| Innocoll Pharmaceuticals Limited | $38.84 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $37.62 | 2022-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $35.18 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $34.95 | 2024 | |
| Vivus LLC | $33.14 | 2024-2025 | Pancreaze |
| Madrigal Pharmaceuticals | $30.04 | 2025 | Rezdiffra |
| Alnylam Pharmaceuticals INC. | $29.38 | 2022 | |
| Braintree Laboratories, INC. | $22.15 | 2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $18.99 | 2022 | |
| Celgene Corporation | $18.66 | 2023 | Zeposia |
| Organon LLC | $17.49 | 2025 | Hadlima |
| Ferring Pharmaceuticals INC. | $16.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliyahu Shemesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.